Tuberculosis (TB) is still the number one cause of death due to an infectious disease.
Pharmacokinetics and pharmacodynamics of anti-TB drugs are key in the optimization of TB …

Multidrug-resistant (MDR) tuberculosis (TB), resistant to isoniazid and rifampicin, continues
to be one of the most important threats to controlling the TB epidemic. Over the last few …

The prolonged treatment duration for multidrug-resistant tuberculosis (MDR-TB) makes
linezolid dosing difficult because of adverse effects associated with long-term use. We …

Antibiotic-resistant tuberculosis continues to be one of the major threats to global
tuberculosis control. After a hiatus of over 40 years in antituberculosis drug development, the …

Introduction Therapeutic drug monitoring (TDM) for personalized dosing of fluoroquinolones
has been recommended to optimize efficacy and reduce acquired drug resistance in the …

Introduction 2018 World Health Organization (WHO) guidelines for the treatment of isoniazid
(H)-resistant (Hr) tuberculosis recommend a four-drug regimen: rifampicin (R), ethambutol …

Phenotypic antimicrobial susceptibility testing (pAST) assesses the ability of antibiotics to
inhibit bacterial growth and has been used for Mycobacterium tuberculosis complex (MTBC) …

A protocol has been developed that allows the synthesis of 2‐aryl/heteroaryl‐4‐quinolones
from readily available, affordable starting materials. The reaction proceeds under microwave …

Abstract Background Mycobacterium tuberculosis (Mtb) strains resistant to isoniazid and
rifampin (multidrug-resistant tuberculosis [MDR-TB]) are increasingly reported worldwide …

Recommendations for treatment of rifampicin-resistant tuberculosis (RR-TB) during
pregnancy and post-partum now include Group A and B antituberculosis drugs. While …